权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Optimization of a novel series of thiazolopyridines for the treatment of SMA

用于治疗 SMA 的新型噻唑并吡啶系列的优化

基本信息

批准号：
8892548
负责人：
ELLIOT J. ANDROPHY
金额：
$ 44.76万
依托单位：
BRIGHAM AND WOMEN'S HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-04-01 至 2017-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8892548
关键词：
Antisense Oligonucleotides Biological Assay Blinded Brain Cell Survival Cells Chemistry Clinical Clinical Research Correlative Study Data Development Dose Drug Kinetics Evaluation Exons Fibroblasts Functional disorder Genetic Genetic Transcription Goals Guidelines Human In Vitro Individual Investigation Lead Length Libraries Longevity Luciferases Measures Medical Messenger RNA Modeling Motor Motor Neurons Mus Muscle Muscle Weakness Neurodegenerative Disorders Oral Oral Administration Patients Permeability Pharmaceutical Chemistry Pharmaceutical Preparations Plasma Process Property Proteins Publishing RNA Reporter SMN protein (spinal muscular atrophy)SMN1 gene SMN2 gene Series Severity of illness Solubility Spinal Muscular Atrophy Structure-Activity Relationship Therapeutic Therapeutic Intervention Transgenic Mice Viral Vector analog design high throughput screening in vitro Assay in vivo innovation intraperitoneal lead series meetings mouse model novel pre-clinical preclinical study prevent programs promoter protein expression public health relevance pyridine research clinical testing research study scaffold screening small molecule tool

项目摘要

DESCRIPTION (provided by applicant): Spinal muscular atrophy (SMA) is a neurodegenerative disease that causes progressive muscle weakness. About 95% of SMA cases are caused by the loss of both copies of the SMN1 gene. The SMN2 gene found in humans is a nearly identical copy of SMN1 and expresses only a small amount of the active SMN protein. While SMN2 cannot fully compensate for the loss of SMN1 in motor neurons, it provides an excellent target for therapeutic intervention. Increased expression of functional full-length SMN protein from the endogenous SMN2 gene should lessen disease severity. Previously, we developed innovative reporter cell assays for inducers of SMN expression, and hit compounds from these assays demonstrated positive effects in the SMN7 mouse model. Very recently, an optimized analog (LDN-2014) demonstrated efficacy both in the very severe SMN7 and moderately severe 2B/- model following intraperitoneal (IP) dosing, although LDN-2014 did not have suitable pharmacokinetic properties for further development. We now have applied this same in vitro assay to screen a novel library of compounds designed and synthesized at the LDDN and identified patentable leads; preliminary optimization has established tractable SAR. Furthermore, potent compounds with good plasma and brain exposures following oral administration have been discovered from this new series. Preliminary investigations indicate that the new series of compounds has a similar mechanism of action as LDN-2014, both of which act post-transcriptionally and stabilize the SMN-protein. The optimization of this novel series as activators of SMN2 protein is a unique approach, which we believe will lead to pre-clinical development candidates for the treatment of SMA. Project Goals: Aim 1 is to conduct medicinal chemistry optimization of the thiazolopyridine series with the objective of identifying 4-6 compounds that have pharmacokinetic properties suitable for pharmacological evaluation in two mouse models of SMA. Derivatives that selectively increase SMN2-luciferase expression without decreasing cell viability will be advanced for secondary screening in SMA derived human fibroblasts. Molecules that increase SMN protein levels by >1.5 fold, and with EC50 < 100 nM, will be advanced into in vitro drug-like property assays (e.g., solubility, microsomal stability, permeability). This iterative process will continue until compounds suitable for mouse oral PK experiments are discovered. Taken together, the in vitro and in vivo data then will be used to select the 4-6 compounds to evaluate in mouse models of SMA. Aim 2 is the characterization of advanced lead compounds in two mouse models of SMA. The 4-6 leading compounds that emerge from Aim 1 will be advanced into the severe (Li) mouse model of SMA. In year 2, the two analogs with the best overall features will be selected for profiling in the less severe SMNRT model. We believe that compounds that emerge from the stringent in vitro and in vivo evaluation we are proposing will be of suitable quality for final pr-clinical evaluation and advancement into clinical studies.